1. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
- Author
-
Shohdy, Kyrillus S, Villamar, Dario M, Cao, Yen, Trieu, Janson, Price, Kristin S, Nagy, Rebecca, Tagawa, Scott T, Molina, Ana M, Sternberg, Cora N, Nanus, David M, Mosquera, Juan Miguel, Elemento, Olivier, Sonpavde, Guru P, Grivas, Petros, Vogelzang, Nicholas J, and Faltas, Bishoy Morris
- Subjects
BLADDER tumors ,DISEASE progression ,SURVIVAL ,RESEARCH ,GENETIC mutation ,SEQUENCE analysis ,RESEARCH methodology ,PROGNOSIS ,EVALUATION research ,TRANSITIONAL cell carcinoma ,COMPARATIVE studies ,RESEARCH funding ,LONGITUDINAL method - Abstract
Background: Targeted sequencing of circulating tumour DNA (ctDNA) is a promising tool to monitor dynamic changes in the variant allele frequencies (VAF) of genomic alterations and predict clinical outcomes in patients with advanced urothelial carcinoma (UC).Methods: We performed targeted sequencing of 182 serial ctDNA samples from 53 patients with advanced UC.Results: Serial ctDNA-derived metrics predicted the clinical outcomes in patients with advanced UC. Combining serial ctDNA aggregate VAF (aVAF) values with clinical factors, including age, sex, and liver metastasis, improved the performance of prognostic models. An increase of the ctDNA aVAF by ≥1 in serial ctDNA samples predicted disease progression within 6 months in 90% of patients. The majority of patients with aVAFs ≤0.7 in three consecutive ctDNA samples achieved durable clinical responses (≥6 months).Conclusions: Serial ctDNA analysis predicts disease progression and enables dynamic monitoring to guide precision medicine in patients with advanced UC. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF